Mesh & Graft-Augmented Prolapse Repair
Mesh and graft-augmented vaginal repairs for pelvic organ prolapse (POP) sit at the edge of contemporary pelvic-floor reconstruction: transvaginal synthetic mesh improves anterior-compartment anatomic outcomes, but it adds mesh-specific morbidity; biologic grafts have not shown a meaningful advantage over native-tissue repair; and since April 2019, no FDA-approved transvaginal mesh products remain available in the United States for POP repair.[1][2][3]
This page covers augmented vaginal POP repairs. It should be read separately from sacrocolpopexy, where mesh is placed abdominally, and from midurethral slings for SUI, which were not removed from the US market by the 2019 FDA POP-mesh order.[1][13]
Current U.S. context
The FDA states that no FDA-approved mesh products are currently marketed in the United States for transvaginal POP repair. Its April 16, 2019 stop-sale order concerns this category, not abdominal sacrocolpopexy mesh or SUI mesh slings. A prior implant does not itself require removal: people without complications can continue routine care, while new bleeding, discharge, pain or dyspareunia warrants assessment.[23]
The technical and trial material below remains useful for understanding previous implants, historical operations, studies and complication care; it does not imply that a transvaginal POP mesh kit is available for routine new use in the United States.
Material Types
| Material | Examples | Current role |
|---|---|---|
| Synthetic nonabsorbable mesh | Type I macroporous monofilament polypropylene | Most studied material; improves anterior anatomic cure but adds exposure, pain, bladder injury, de novo SUI, and repeat-surgery risk.[1][3] |
| Synthetic absorbable mesh | Polyglactin / Vicryl-type materials | Does not show durable benefit over native-tissue repair.[3] |
| Autologous biologic graft | Rectus fascia | Avoids permanent synthetic material but adds donor-site morbidity and lacks strong POP benefit data. |
| Allograft / homologous graft | Cadaveric fascia lata | Studied historically; no consistent durable advantage over native repair.[2][3] |
| Xenograft | Porcine dermis, porcine small intestinal submucosa | No meaningful benefit over native tissue in contemporary reviews; posterior-compartment outcomes may be worse in some trials.[1][3] |
Efficacy by Compartment
| Compartment | Synthetic mesh | Biologic graft | Practical conclusion |
|---|---|---|---|
| Anterior | Improves anatomic cure and reduces bulge recurrence compared with native-tissue repair, but subjective outcomes are often similar.[1][2][4][5] | Minimal benefit; similar prolapse awareness and reoperation rates compared with native tissue.[1][3] | Anatomic advantage must be weighed against mesh-specific morbidity. In the US, no approved TVM POP product remains available. |
| Posterior | Does not improve outcomes.[1][3] | Does not improve outcomes and may worsen anatomic results in some trials.[1][3] | Do not routinely use mesh or biologic grafts for posterior colporrhaphy. |
| Apical | Native-tissue vaginal repairs have similar prolapse awareness and reoperation compared with TVM in some analyses, while TVM adds mesh complications.[6] ASPIRe met its prespecified TVM-versus-SCP noninferiority comparison for post-hysterectomy vault prolapse, without establishing equivalence or TVM superiority over native tissue.[7] | No clear durable role. | Sacrocolpopexy is usually the mesh-based durability benchmark; historical vaginal mesh evidence must be interpreted alongside the product and local regulatory context. |
Trial Anchors
PROSPECT
The PROSPECT trial randomized 1,348 women undergoing primary transvaginal anterior and / or posterior compartment prolapse surgery. Augmentation with either synthetic mesh or biologic graft did not improve prolapse symptom scores or quality of life at 1 or 2 years compared with standard repair. Mesh complications occurred in 12% of mesh-exposed women within 2 years.[5]
FDA 522 study
An FDA-mandated 522 study comparing transvaginal mesh with native tissue repair reported 36-month composite success of 89.3% for mesh versus 80.2% for native tissue, demonstrating noninferiority but not superiority on the primary endpoint. These study endpoints did not establish a favorable FDA benefit-risk determination or restore U.S. marketing availability.[8][24]
PROSPERE
The PROSPERE multicenter trial comparing laparoscopic sacrocolpopexy with transvaginal mesh for primary cystocele showed similar long-term success rates, but grade III or higher complications were more common after TVM (8.7% vs. 2%).[9]
ASPIRe: post-hysterectomy vault prolapse
ASPIRe randomized 376 women, of whom 360 underwent study surgery, to native-tissue repair, sacrocolpopexy or transvaginal mesh. Modeled 36-month composite failure was 43%, 28% and 29%, respectively. Sacrocolpopexy was superior to native tissue; the transvaginal-mesh comparison with native tissue did not meet the trial's adjusted superiority threshold. TVM met a prespecified noninferiority margin versus sacrocolpopexy, which is not equivalence. Most failures were anatomical rather than repeat operations.[7]
This trial concerned post-hysterectomy vault prolapse, not uterine preservation, and used the now-unmarketed Uphold LITE vaginal product. The prolapse principles page contains the corrected endpoint and analysis details.
Mesh-Specific Complications
For the canonical complications and removal reference — IUGA / ICS classification, complete-vs-partial removal evidence, surgical-approach algorithm, ACOG Committee Opinion 694 management framework — see Mesh Complications & Removal. The summary below is the indication-and-augmentation-context view.
The 2024 Cochrane review included 51 trials. Its estimates combine different products, compartments and follow-up periods; they are study summaries rather than a prediction for one implant or patient.[3]
| Complication | Signal |
|---|---|
| Vaginal mesh exposure | 11.8% overall; 6.1% required surgical intervention.[3] |
| Repeat surgery | Total repeat surgery for prolapse, SUI, or mesh exposure is higher with mesh.[1] |
| De novo SUI | Increased after mesh-augmented repair.[3] |
| Bladder injury | Higher with mesh placement.[3] |
| Dyspareunia / pain | Pain and dyspareunia are important reported complications; rates depend on baseline symptoms, sexual activity, implant and follow-up.[3][10] |
| Erosion range by compartment burden | Reported erosion rates range from 1.4-19% after anterior wall placement and 3-36% when mesh spans multiple compartments.[2] |
A retrospective study examined associations between mesh erosion and patient/procedure features. These associations should not be treated as a universal causal risk score; smoking, tissue health and the precise operation belong in individualized counseling.[11] Mesh complications are not purely technical; the host response to polypropylene is shaped by the vaginal hormonal and microbial environment, implant porosity, surface area, and chronic immune activation.[12]
U.S. regulatory timeline
| Year | Event |
|---|---|
| 2008 | FDA public-health notification about complications of urogynecologic mesh. |
| 2011 | Additional FDA safety communication about serious transvaginal POP mesh complications. |
| 2016 | Transvaginal POP mesh reclassified as Class III devices. |
| 2019 | FDA ordered the remaining transvaginal POP mesh manufacturers to stop sales and distribution. |
These events and subsequent 522-study assessments are summarized by the FDA. Regulatory availability outside the United States is jurisdiction- and product-specific.[23][24]
Technique and selection context
Native-tissue vaginal repair and abdominal/minimally invasive sacrocolpopexy are the main reconstructive alternatives discussed for new U.S. cases, alongside conservative management. Historical recommendations for selected vaginal mesh use should not be presented as current availability of a kit. Synthetic or biologic augmentation has not established a routine advantage for posterior vaginal wall repair.[1][3][14][23]
When reviewing a previous augmented repair, record the material, operative route, compartment, fixation pattern and any concomitant surgery. Manufacturer documentation and the original operative report are useful sources for device identification and placement; a randomized trial is not required to establish those descriptive facts. Clinical comparative evidence answers a different question: whether a particular augmentation improves outcomes enough to justify its harms.
Mesh and Graft Complication Management
ACOG / AUGS guidance on mesh and graft complications emphasizes symptom-driven management and specialist referral for complex pain, erosion, urinary tract involvement, or failed prior excision.[15]
| Presentation | Management frame |
|---|---|
| Asymptomatic small exposure | Expectant management is acceptable for monofilament macroporous mesh.[15] |
| Small symptomatic exposure | Trial topical vaginal estrogen, local care, and observation may be reasonable before excision.[15] |
| Bleeding, discharge, partner pain, or recurrent exposure | Office trimming may be insufficient; consider operative partial excision with counseling about recurrence and pain persistence.[15][16] |
| Pain / dyspareunia without visible exposure | The most difficult phenotype; mesh removal may not resolve pain. In one series, complete pain resolution occurred in only about half after operative management.[17] |
| Urinary tract erosion, fistula, abscess, severe pain, or complex prior excision | Refer to FPMRS / reconstructive specialist; evaluate with cystoscopy, imaging, and multidisciplinary pain care when indicated.[15] |
For an asymptomatic person, the presence of an implant alone is not an indication for removal. For symptoms, match treatment to the identified problem and explain that removal may not resolve pain and may introduce recurrent prolapse or incontinence.[15]
Sacrocolpopexy vs. Transvaginal Mesh
Sacrocolpopexy and transvaginal mesh use different routes, dissection and fixation. Their comparative benefit-risk findings should be interpreted for the actual operations studied. A systematic review and meta-analysis found lower mesh complication rates, lower de novo dyspareunia, and similar anatomic / subjective success with sacrocolpopexy compared with TVM.[18] The VIGI-MESH registry similarly found fewer serious complications after laparoscopic sacrocolpopexy than TVM at 1 year, with low recurrence reoperation rates.[19]
Long-term data complicate the story: a Finnish nationwide cohort with mean 7.4-year follow-up found similar prolapse reoperation rates across native tissue, transvaginal mesh, and abdominal mesh, with differences in recurrence site; observational comparisons can be confounded by procedure selection.[20]
Long-Term Outcomes
Mesh complications do not disappear after the early postoperative window. A New York State observational cohort of 54,194 women found an association between mesh POP repair and higher 5-year reintervention risk than native tissue repair (8.8% vs. 6.3%; HR 1.40).[21] Long-term follow-up cohorts confirm that recurrence, reoperation, and mesh complications remain surveillance issues years after the index procedure.[20]
Future Directions
Biologic and biomimetic graft materials aim to reproduce the mechanical advantages of synthetic mesh while improving tissue integration and reducing chronic host response. For now, the clinical translation gap remains large: preclinical promise has not yet produced a durable, low-morbidity vaginal graft that clearly outperforms native tissue repair.[22] The 2024 Cochrane review concludes that transvaginal mesh has limited utility in primary surgery and that any ongoing use should occur with ethical oversight and outcomes reported to regulatory bodies.[3]
See Also
- Principles of Prolapse Repair - symptom-driven decision-making and native-tissue first-line framework.
- Anterior Colporrhaphy - native anterior repair.
- Posterior Colporrhaphy - native posterior repair; mesh / grafts not routinely recommended.
- Sacrocolpopexy - abdominal mesh benchmark for apical durability.
- Fistula Repair - complex erosions, fistulae, and radiation-related pelvic tissue problems.
- GSM - hypoestrogenic vaginal tissue, topical estrogen, and cancer-survivor considerations.
Videos
References
1. Pelvic organ prolapse: ACOG Practice Bulletin, Number 214. Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519
2. Schimpf MO, Abed H, Sanses T, et al. Graft and mesh use in transvaginal prolapse repair: a systematic review. Obstet Gynecol. 2016;128(1):81-91. doi:10.1097/AOG.0000000000001451
3. Yeung E, Baessler K, Christmann-Schmid C, et al. Transvaginal mesh or grafts or native tissue repair for vaginal prolapse. Cochrane Database Syst Rev. 2024;3:CD012079. doi:10.1002/14651858.CD012079.pub2
4. Capobianco G, Sechi I, Muresu N, et al. Native tissue repair versus transvaginal mesh interventions for the treatment of anterior vaginal prolapse: systematic review and meta-analysis. Maturitas. 2022;165:104-112. doi:10.1016/j.maturitas.2022.07.013
5. Glazener CM, Breeman S, Elders A, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet. 2017;389(10067):381-392. doi:10.1016/S0140-6736(16)31596-3
6. Maher C, Yeung E, Haya N, et al. Surgery for women with apical vaginal prolapse. Cochrane Database Syst Rev. 2023;7:CD012376. doi:10.1002/14651858.CD012376.pub2
7. Menefee SA, Richter HE, Myers D, et al. Apical suspension repair for vaginal vault prolapse: a randomized clinical trial. JAMA Surg. 2024;159(8):845-855. doi:10.1001/jamasurg.2024.1206
8. Kahn B, Varner RE, Murphy M, et al. Transvaginal mesh compared with native tissue repair for pelvic organ prolapse. Obstet Gynecol. 2022;139(6):975-985. doi:10.1097/AOG.0000000000004794
9. Lucot JP, Cosson M, Verdun S, et al. Long-term outcomes of primary cystocele repair by transvaginal mesh surgery versus laparoscopic mesh sacropexy: extended follow up of the PROSPERE multicentre randomised trial. BJOG. 2022;129(1):127-137. doi:10.1111/1471-0528.16847
10. Yang J, Zhang K, Han J, et al. Long-term observation on postoperative recurrence and complications of transvaginal mesh surgery for pelvic organ prolapse. Gynecol Obstet Invest. 2022;87(1):30-37. doi:10.1159/000520979
11. Cetin Arslan H, Arslan K. Risk factors and outcomes of vaginal mesh erosions after pelvic reconstructive surgery: a retrospective cohort study. Medicine (Baltimore). 2025;104(19):e42442. doi:10.1097/MD.0000000000042442
12. Abhari RE, Izett-Kay ML, Morris HL, Cartwright R, Snelling SJB. Host-biomaterial interactions in mesh complications after pelvic floor reconstructive surgery. Nat Rev Urol. 2021;18(12):725-738. doi:10.1038/s41585-021-00511-y
13. Winkelman WD, Modest AM, Richardson ML. U.S. Food and Drug Administration statements about transvaginal mesh and changes in apical prolapse surgery. Obstet Gynecol. 2019;134(4):745-752. doi:10.1097/AOG.0000000000003488
14. Pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2019;25(6):397-408. doi:10.1097/SPV.0000000000000794
15. American College of Obstetricians and Gynecologists / American Urogynecologic Society. Management of mesh and graft complications in gynecologic surgery. Committee Opinion No. 694. 2017. Accessed September 20, 2026.
16. Abbott S, Unger CA, Evans JM, et al. Evaluation and management of complications from synthetic mesh after pelvic reconstructive surgery: a multicenter study. Am J Obstet Gynecol. 2014;210(2):163.e1-163.e8. doi:10.1016/j.ajog.2013.10.012
17. Crosby EC, Abernethy M, Berger MB, et al. Symptom resolution after operative management of complications from transvaginal mesh. Obstet Gynecol. 2014;123(1):134-139. doi:10.1097/AOG.0000000000000042
18. Zhang CY, Sun ZJ, Yang J, et al. Sacrocolpopexy compared with transvaginal mesh surgery: a systematic review and meta-analysis. BJOG. 2021;128(1):14-23. doi:10.1111/1471-0528.16324
19. Fritel X, de Tayrac R, de Keizer J, et al. Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI-MESH registry. BJOG. 2022;129(4):656-663. doi:10.1111/1471-0528.16892
20. Wihersaari O, Karjalainen P, Tolppanen AM, et al. Prolapse recurrence, methods of reoperation, and long-term mesh complications: a nationwide follow-up study. Acta Obstet Gynecol Scand. 2025. doi:10.1111/aogs.70083
21. Chughtai B, Mao J, Asfaw TS, et al. Long-term device outcomes of mesh implants in pelvic organ prolapse repairs. Obstet Gynecol. 2020;135(3):591-598. doi:10.1097/AOG.0000000000003689
22. Whooley J, Cunnane EM, Do Amaral R, et al. Stress urinary incontinence and pelvic organ prolapse: biologic graft materials revisited. Tissue Eng Part B Rev. 2020;26(5):475-483. doi:10.1089/ten.TEB.2020.0024
23. U.S. Food and Drug Administration. Urogynecologic surgical mesh implants. Accessed September 20, 2026.
24. U.S. Food and Drug Administration. FDA activities: urogynecologic surgical mesh. Accessed September 20, 2026.